Ultimately, with prospective clinical trial data likely to be limited, greater pre-clinical and translational evidence will be crucial to elucidate the role for anti-angiogenic therapy in ALK rearranged NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.